
ALC Stock Forecast & Price Target
ALC Analyst Ratings
Bulls say
Alcon is a leading global visioncare and surgical company with strong brands, innovative products, and a global reach, making it well-positioned for growth in the global eye care market. The recent spin-off from Novartis offers increased focus and potential for improved profitability as Alcon continues to invest in new products and expands its presence in key markets. The recent launch of new products, such as Dailies Total1 and Centurion, coupled with potential margin improvement, could result in higher-than-expected revenue and EPS growth for the company.
Bears say
Alcon is facing potential challenges in its visioncare and surgical segments, with increased competition and potential share loss to competitors like Johnson & Johnson's PureSee. Despite a strong installed base of surgical equipment, Alcon may struggle to maintain market share without the successful launch of next-gen products like Vivity, which is not expected until 2027. While Alcon has introduced a large stock repurchase authorization and continues to pursue M&A deals, the company's valuation remains a concern with a multiple discount to historical averages and relatively high tariffs impacting earnings. In addition, the recent recall of its IOL product in China may pose a risk to future sales and share recovery.
This aggregate rating is based on analysts' research of Alcon Inc. - Registered Shares and is not a guaranteed prediction by Public.com or investment advice.
ALC Analyst Forecast & Price Prediction
Start investing in ALC
Order type
Buy in
Order amount
Est. shares
0 shares